Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.42 -0.20 (-0.75%)
Streaming Delayed Price Updated: 3:30 PM EST, Dec 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program. 
Via Benzinga
Exposures Product Safety
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
Put your money to work by investing in these three high-quality dividend stocks. 
Via The Motley Fool
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure. 
Via Investor's Business Daily
Exposures Product Safety
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
Creative Biolabs: The Way ADCs Are Made Has Changed
Via Get News
US Stock: Pfizer
Pfizer is engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. 
Via Talk Markets
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
What's Going On With Pfizer Stock On Thursday?
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 Bargain Stocks Near 52-week Lows
Three undeniable bargains came into play after the market's disappointment sell off, investors still have double-digit upside ahead of them in these names 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Wednesday Trading
Via Investor Brand Network
Exposures COVID-19
Pfizer Declares Second-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
Discover the top dividend stocks for prolonged wealth in 2024 in pharmaceuticals, integrated telecommunications, drug retail, and tobacco. 
Via InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
3 Defensive Stocks To Protect Your Portfolio In 2024
Alcohol, tobacco, and drugs as bulwarks against market shocks, and these three stocks are now trading under low ballparks. 
Via Talk Markets
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth. 
Via InvestorPlace
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
This Vanguard growth fund is home to some of the world's most innovative companies. 
Via The Motley Fool
3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years
These are the undervalued blue-chip stocks to buy as they represent fundamentally strong ideas poised for accelerated growth. 
Via InvestorPlace
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
Capturing Consumer Spending on Health Care with XLV
Capturing Consumer Spending on Health Care with XLV 
Via News Direct
3 Stocks Under $50 You Can Buy Hand Over Fist Right Now
A little up-front investment can go a long way with these three stocks. 
Via The Motley Fool
If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today
The answer to that question will either make you wince or smile. 
Via The Motley Fool
The 3 Most Overlooked Stocks Set for a Triple-Digit Comeback
Learn how these overlooked stocks are set for a massive resurgence with leads in pharmaceutical, broadline retail and interactive media. 
Via InvestorPlace
3 No-Brainer Stocks to Buy With $100 Right Now
A modest amount of money can go a long way in the stock market when it's put to work in time-tested businesses with well-defined competitive advantages. 
Via The Motley Fool
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost... 
Via Benzinga
Pneumococcal Pneumonia Vaccination Can Save Your Life
Via StatePoint Media
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.